8 active not recruiting, 3 completed, 3 recruiting, 1 terminated. 15 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Active not recruiting 8, Completed 3, Recruiting 3, Terminated 1 |
| Phase 2 | 3 | Active not recruiting 2, Recruiting 1 |
Follow CT-P10: new trials by email Literature Review of CT-P10 trials Research Report on CT-P10
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 271 | 2027-07-27 | 2026-11-17 |
| Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial Biospecimen Collection, Computed Tomography, Cyclophosphamide - Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 102 | 2026-08-04 | 2026-10-13 |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma Biospecimen Collection, Computed Tomography, Mosunetuzumab - Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features | Phase 3 | Recruiting | National Cancer Institute (NCI) | 600 | 2024-10-23 | 2026-11-18 |
| Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Aspiration, Busulfan - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 66 | 2023-03-15 | 2026-07-30 |
| Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Primary Mediastinal Large B-Cell Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 244 | 2021-10-05 | 2026-11-04 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 422 | 2021-05-20 | 2026-11-12 |
| Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 363 | 2019-10-22 | 2026-11-12 |
| Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate - Mantle Cell Lymphoma | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 689 | 2017-11-27 | 2026-09-14 |
| To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma CT-P10, Rituxan - Follicular Lymphoma | Phase 3 | Completed | Celltrion | 258 | 2015-11-09 | 2021-04-08 |
| Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma Quality-of-Life Assessment, Rituximab, Yttrium Y-90 Ibritumomab Tiuxetan - Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma | Phase 3 | Terminated | Mayo Clinic | 20 | 2015-02-11 | 2025-07-09 |
| PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis CT-P10, Rituxan, MabThera - Rheumatoid Arthritis | Phase 3 | Completed | Celltrion | 384 | 2014-08-01 | 2021-12-16 |
| To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan Rituxan, CT-P10, Cyclophosphamide - Lymphoma, Follicular | Phase 3 | Completed | Celltrion | 140 | 2014-07-14 | 2020-01-29 |
| Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Blinatumomab - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 488 | 2014-05-19 | 2026-11-18 |
| Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Cyclophosphamide, Fludarabine Phosphate, Ibrutinib - Anemia, Chronic Lymphocytic Leukemia | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 529 | 2014-03-10 | 2026-08-28 |
| Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Bendamustine Hydrochloride, Biospecimen Collection, Bone Marrow Aspiration - Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 547 | 2014-01-15 | 2026-11-16 |
Burkitt Lymphoma (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia (1) · Arthritis, Rheumatoid (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Mantle-Cell (1) · Myelodysplastic Syndromes (1)
National Cancer Institute (NCI) (8) · Celltrion (3) · Children's Oncology Group (1) · ECOG-ACRIN Cancer Research Group (1) · Mayo Clinic (1) · SWOG Cancer Research Network (1)
United States (12) · Canada (4) · Australia (2) · Puerto Rico (2) · Israel (1) · Saudi Arabia (1) · South Korea (1)
DaeHyun Yoo, M.D., Ph.D (1) · Elizabeth A Brem (1) · Heather J Symons (1) · Jennifer A Woyach (1) · Jeremy S Abramson (1) · Kristie A Blum (1) · Lisa G Roth (1) · Mark R Litzow (1) · Mazyar Shadman (1) · Nilanjan Ghosh (1) · SungHyun Kim (1) · Tait D Shanafelt (1) · Thomas E. Witzig, M.D. (1) · Timothy S Fenske (1)
PMID 28712940, PMID 30010481, PMID 30389036, PMID 30501481, PMID 30719632, PMID 31184752, PMID 31365801, PMID 32589970, PMID 33288485, PMID 33439748, PMID 34274940, PMID 34477816, PMID 34634256, PMID 34686445, PMID 34686472, PMID 34865212, PMID 35427411, PMID 36485104, PMID 37801678, PMID 38215395, PMID 39047240, PMID 42660130, PMID 42832396
U10CA180820 (3), U10CA180821 (3), U10CA180888 (3), U10CA021115 (2), U10CA180886 (2), U24CA196172 (2), K23CA178183 (1), R01CA183444 (1), R01CA193541 (1), U10CA031946 (1)